🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

IOL Chemicals and Pharmaceuticals Limited IOLCP NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.iolcp.com
Company Profile ↓
₹175.34
+95.19% 1Y
Mkt Cap₹5,146.71 Cr
P/E37.39
P/B2.76
Div. Yield0.58%
52W High₹175.34
52W Low₹68.15
Book Value₹61.27
EPS (TTM)₹4.69

Company Overview

IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company operates through, Chemical and Pharmaceutical segments. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, and paracetamol. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, anti-epileptic, anti-hypertensive, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 37.4, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.08.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,319.06 Cr (+11.5% YoY); net profit ₹137.64 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +11.5%, earnings +36.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 1.7%, profit CAGR -0.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:1.75%
1 Year:11.54%

Compounded Profit Growth

5 Years:-0.36%
1 Year:36.18%

Stock Price Performance

1 Year:+95.19%
6 Months:+126.82%
3 Months:+104.91%
1 Month:+31.32%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹68.15 ₹175.34
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)77.47 · Overbought
Price Performance
1M+31.32%
3M+104.91%
6M+126.82%
1Y+95.19%
Valuation vs Sector

P/E of 37.39 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -0.4% CAGR over 5 years.
  • RSI at 77 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
37.39
Industry PE
39.97
Forward P/E
23.69
PEG Ratio
-
Book Value
₹61.27
Price to Book
2.76
P/S
2.14
EV/EBITDA
18.22
Dividend Yield
0.58%

Growth (CAGR)

Revenue 5Y
1.75%
Profit 5Y
-0.36%
Revenue (YoY)
11.54%
Earnings (YoY)
36.18%

Profitability & Returns

ROCE
10.49%
ROE
7.65%
ROA
5.32%
Profit Margin
5.94%
Op Margin
8.14%
Gross Margin
35.88%
EPS (Latest Qtr)
₹1.81
EPS (TTM)
₹4.69

Balance Sheet & Liquidity

Debt/Equity
0.08
Quick Ratio
1.24
Current Ratio
1.78
Debt
₹135.42 Cr
Total Assets
₹2,586.95 Cr
Current Assets
₹1,227.63 Cr
Working Capital
₹537.45 Cr

Ownership

Promoter Holding
66.09%
Chg in Prom Hold
-0.89%
FII / Inst Holding
1.27%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹5,146.71 Cr
Total Revenue (TTM)
₹2,319.06 Cr
EBITDA
₹279.14 Cr
Free Cash Flow
₹41.33 Cr
Operating Cash Flow
₹214.32 Cr
Shares Outstanding
₹29.35 Cr
Gross Margin
35.88%
Payout Ratio
21.32%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IOLCP IOL Chemicals and Pharmaceuticals Limited NSEPHARMA 175.34 37.39 ₹5,146.71 Cr 0.58% 10.49% 7.65% 1.75% -0.36%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 587.00 Cr563.00 Cr545.00 Cr520.00 Cr504.00 Cr502.00 Cr526.00 Cr523.00 Cr527.78 Cr551.69 Cr567.53 Cr580.39 Cr619.45 Cr
Cost of Revenue --------345.79 Cr364.33 Cr368.17 Cr382.44 Cr372.26 Cr
Gross Profit --------181.99 Cr187.36 Cr199.36 Cr197.95 Cr247.19 Cr
Operating Expenses 492.00 Cr491.00 Cr481.00 Cr476.00 Cr454.00 Cr451.00 Cr484.00 Cr476.00 Cr137.79 Cr145.09 Cr162.27 Cr160.85 Cr175.01 Cr
Operating Income 83.00 Cr59.00 Cr48.00 Cr28.00 Cr34.00 Cr34.00 Cr24.00 Cr28.00 Cr44.20 Cr42.27 Cr37.09 Cr37.10 Cr72.18 Cr
EBITDA 95.00 Cr73.00 Cr64.00 Cr44.00 Cr50.00 Cr51.00 Cr42.00 Cr47.00 Cr67.28 Cr69.51 Cr63.96 Cr51.36 Cr94.30 Cr
Interest Expense 5.00 Cr4.00 Cr4.00 Cr4.00 Cr3.00 Cr2.00 Cr4.00 Cr4.00 Cr4.03 Cr4.23 Cr3.48 Cr3.63 Cr3.20 Cr
Pretax Income 87.00 Cr61.00 Cr51.00 Cr32.00 Cr37.00 Cr40.00 Cr26.00 Cr28.00 Cr44.70 Cr45.51 Cr40.49 Cr27.55 Cr70.81 Cr
Tax Provision 22.62 Cr15.25 Cr13.26 Cr8.96 Cr9.62 Cr9.60 Cr6.76 Cr7.28 Cr13.28 Cr11.58 Cr10.52 Cr6.97 Cr17.65 Cr
Net Income 65.00 Cr46.00 Cr38.00 Cr23.00 Cr28.00 Cr30.00 Cr19.00 Cr21.00 Cr31.42 Cr33.93 Cr29.97 Cr20.58 Cr53.16 Cr
Diluted EPS 2.211.561.290.790.941.020.650.701.071.161.020.701.81

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -2,201.69 Cr2,118.96 Cr2,079.21 Cr2,319.06 Cr
Cost of Revenue -1,576.71 Cr1,423.10 Cr1,391.85 Cr1,487.08 Cr
Gross Profit -624.98 Cr695.86 Cr687.36 Cr831.98 Cr
Operating Expenses -444.81 Cr527.93 Cr557.05 Cr643.22 Cr
Operating Income -180.17 Cr167.93 Cr130.31 Cr188.76 Cr
EBITDA -245.50 Cr255.40 Cr224.71 Cr279.14 Cr
Interest Expense -10.69 Cr10.84 Cr14.76 Cr14.55 Cr
Pretax Income -188.65 Cr181.65 Cr137.96 Cr184.36 Cr
Tax Provision -49.51 Cr47.22 Cr36.89 Cr46.72 Cr
Net Income -139.14 Cr134.43 Cr101.07 Cr137.64 Cr
Diluted EPS -4.744.583.444.69

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -2,022.13 Cr2,244.40 Cr2,382.07 Cr2,586.95 Cr
Current Assets -920.39 Cr1,119.77 Cr1,151.34 Cr1,227.63 Cr
Cash & Equivalents -1.39 Cr7.69 Cr78.17 Cr65.35 Cr
Inventory -325.52 Cr424.84 Cr360.62 Cr371.07 Cr
Receivables -505.28 Cr471.23 Cr513.69 Cr603.13 Cr
Total Liabilities -514.41 Cr632.89 Cr694.41 Cr788.40 Cr
Current Liabilities -456.26 Cr560.00 Cr609.91 Cr690.18 Cr
Long Term Debt -0000
Total Debt -79.81 Cr32.76 Cr117.04 Cr135.42 Cr
Total Equity -1,507.72 Cr1,611.51 Cr1,687.66 Cr1,798.55 Cr
Shares Outstanding -29.35 Cr29.35 Cr29.35 Cr29.35 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -122.27 Cr289.78 Cr178.62 Cr214.32 Cr
Investing Cash Flow --120.00 Cr-190.98 Cr-154.18 Cr-198.11 Cr
Financing Cash Flow --4.11 Cr-92.50 Cr46.04 Cr-29.03 Cr
Capital Expenditure --211.82 Cr-274.17 Cr-213.55 Cr-172.99 Cr
Free Cash Flow --89.55 Cr15.61 Cr-34.93 Cr41.33 Cr
Net Change in Cash --1.84 Cr6.30 Cr70.48 Cr-12.82 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -28.4%32.8%33.1%35.9%
Operating Margin % -8.2%7.9%6.3%8.1%
Net Margin % -6.3%6.3%4.9%5.9%
ROE % -9.2%8.3%6.0%7.7%
ROCE % -11.5%10.0%7.4%10.0%

Shareholding Pattern

Insiders
66.09%
Institutions
1.27%
Public Float
3.76%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IOLCP

Google News Fri, 26 Jun 2026

IOLCP Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9PUWdjYWZmT0ExVHFsZFBHU2dJMDVEeTI1YnA2WDE4NG5xWC1CY3g4RldiQjFiWFppY0RMS3JtbHNUWHpOY2RYbzlVSUI5d2VmaEg1WWhwUkRrUEQwalhudUVRQVc2MHFwTzZtM05oYVlLUzRjNHkw?oc=5" target="_blank">IOLCP F…

Google News Sun, 15 Feb 2026

₹110 - That's What Analysts Think IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) Is Worth After These Results - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxPb2JsYVF6RXBwWlZnMmJkZUpvLXpXWFF6WWFqbF9tZTdJSWZKUnFybDNFOG83VFhxNWxoaTNiMXRmcFd4cGNENzNfNGdWampvbFRrZEZLQWt3TWlmbUs0Q09mNnNGVC0tRGZoNlFXZ3ctd3QwLWFxUzhYam40WDQ1ZEtzNGNsUFlGWVJ3WF…

Google News Wed, 20 May 2026

IOL Chemicals Posts 68% YoY Profit Growth to ₹53.2 Crore in Q4 Results - Sahi

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdkV6S2ZvOE43UlBLQkwzdEJ6Zlg5S0dhMjlKM21ZakczZ1pLcU52Z1BaQ204YUc3NkhSeXQ2N2N4Ymh1SnJyWVB6LXd0LXI1em9uMDNtbVYtcVozTnk5RnV4Wktma25jZ2ROOVpfLV9TYzdRUnhoYXJQTGlDaUNjUmNGSUNGcVpibE56dk…

Google News Fri, 20 Mar 2026

NCVI Enterprises Increases IOL Chemicals Stake with Additional Share Acquisition - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQc1QtTHBZREFQRmI5YlU2U2Vrajd5RkQ0QlVRLVlLT0cwMGgtVGR3d1V6N0RQOWNaMlF4aXgydkV2MnBVRHR1NEItQjI2OTJlTGR0Y0hSWFBYV1RBRkJTRDB5TER6c19mU1l2ZnZiVnprQTRpUk4tRFljWHlEODJfWXhTSE1FYk5yWnpMcn…

Google News ue, 09 Sep 2025

These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well - simplywall.st

<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxNWFdxelBFclhGUDI3VDVOOUpKa0ZvSXIwWlM3V1ZZVndqSjltX2V0Zng4ZWNEOC1vak1YVE9ab05rOGVLQ3NaWGpYaEtOVWd0ajBSbGI5bzQtY3BqQVJmZHhXQkx0Q1RTdnEtNDYwTVhiZEVMcWVkZ1BXX3Z5RVkwalZNSDk4YVk0d25TeE…

Google News Wed, 20 May 2026

IOL Chemicals Q4 Results: Stock ends 9% higher after revenue, margin growth - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOeXVybS1Xbjg5MDBRM3E5VHJwZFBrMi11akl0OFc0WlN5LTYzQVpXbkwwNHZsYmoxdlMxOXBSSERqQUJRZkdGNWx4NTZvVjBaMVhkeFBCVDJsWjVVV2Y0UGRMTUI2Q1B6MnY2VjdoblZZZ0lPYlE4ZktoRW16TFVidzJ0OENBR0FsYVVJOW…

IOLCP — Frequently Asked Questions

What is the current share price of IOL Chemicals and Pharmaceuticals Limited (IOLCP)?

As of 2026-07-15 09:52 IST, IOL Chemicals and Pharmaceuticals Limited (IOLCP) trades at ₹175.34 on NSE. Its 52-week range is ₹68.15 to ₹175.34.

What is the market capitalisation of IOLCP?

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has a market capitalisation of ₹5,146.71 Cr on NSE.

What is the P/E ratio of IOLCP?

IOLCP trades at a trailing price-to-earnings (P/E) ratio of 37.39. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.76.

Does IOLCP pay a dividend?

IOL Chemicals and Pharmaceuticals Limited (IOLCP) currently offers a dividend yield of 0.58%.

What is the return on equity (ROE) of IOLCP?

IOLCP has a return on equity (ROE) of 7.65%. Its return on capital employed (ROCE) is 10.49%.

Is IOLCP a good stock to buy?

This page provides a data-driven analysis of IOL Chemicals and Pharmaceuticals Limited (IOLCP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space